XENETIC BIOSCIENCE, INCORPORATED LEDGEMONT RESEARCH CENTER LEXINGTON, MALease Agreement • February 18th, 2015 • Xenetic Biosciences, Inc. • Pharmaceutical preparations
and - Exclusive Patent And Know How Licence and Manufacturing AgreementExclusive Patent and Know How Licence and Manufacturing Agreement • February 18th, 2015 • Xenetic Biosciences, Inc. • Pharmaceutical preparations • New York
and - SERVICE AGREEMENTService Agreement • February 18th, 2015 • Xenetic Biosciences, Inc. • Pharmaceutical preparations
Counterpart Lease relating to 3rd Floor Rear, Greener House, 68 Haymarket, London SW1 Dated 20 March 2012 Her Majesty the Queen (1) The Crown Estate Commissioners (2) Xenetic Biosciences plc (3)Lease Agreement • February 18th, 2015 • Xenetic Biosciences, Inc. • Pharmaceutical preparations
DATED: 3 November 2009 - and - SERVICE AGREEMENTService Agreement • February 18th, 2015 • Xenetic Biosciences, Inc. • Pharmaceutical preparations
Final Version (11 November 2009) Private and Confidential DATED [ ]Collaboration, Licence and Development Agreement • February 18th, 2015 • Xenetic Biosciences, Inc. • Pharmaceutical preparations • England and Wales
DATED 4 August 2011 SUBSCRIPTION AGREEMENT in respect of ordinary shares in the capital of Lipoxen plcSubscription Agreement • February 18th, 2015 • Xenetic Biosciences, Inc. • Pharmaceutical preparations
EMPLOYMENT AGREEMENTEmployment Agreement • February 18th, 2015 • Xenetic Biosciences, Inc. • Pharmaceutical preparations • Massachusetts
This Employment Agreement (“Agreement”) is entered into as of this 30th day of April 2012 (the “Effective Date”) by and between Xenetic Bioscience, Inc, a Delaware corporation, having its principal Executive office at 12302 Main Campus Drive, Lexington, Massachusetts 02421 (the “Company”), and Henry Hoppe IV, an individual residing at 12302 Main Campus Drive, Lexington, Massachusetts 02421 (the “Executive”).
SIXTH AMENDMENT TO THE EXCLUSIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTExclusive Research, Development and License Agreement • February 18th, 2015 • Xenetic Biosciences, Inc. • Pharmaceutical preparations
This Sixth Amendment to Exclusive Research, Development and License Agreement (this “Sixth Amendment”) is made and entered into as of this 29th day of January, 2014 by and among Baxter Healthcare SA, a Swiss corporation having a principal place of business at Postfach, 8010, Zurich, Switzerland (hereinafter “BHSA”) Baxter Healthcare Corporation, a Delaware corporation having a principal place of business at 1 Baxter Parkway, Deerfield, Illinois (“BHC” and together with BHSA, “Baxter”) and Lipoxen Technologies Limited, having a place of business at London Bioscience Innovation Centre, 2 Royal College Street, London NW1 ONH, England (hereinafter “Lipoxen”) to amend the terms of that certain Exclusive Research, Development and License Agreement, dated August 15, 2005 among, Lipoxen and Baxter (the “Agreement”) (as amended). Baxter and Lipoxen are each referred to herein as a “Party” and collectively as the “Parties”.
LETTER AGREEMENTLetter Agreement • February 18th, 2015 • Xenetic Biosciences, Inc. • Pharmaceutical preparations
SECOND AMENDMENT TO EXCLUSIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTExclusive Research, Development and License Agreement • February 18th, 2015 • Xenetic Biosciences, Inc. • Pharmaceutical preparations
This SECOND AMENDMENT TO EXCLUSIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENT (this “Amendment”) is made and entered into as of this 28TH day of May, 2009 by and among Lipoxen Technologies Limited, a company registered in England and Wales with company number 03401495 and having its registered office at London Bioscience Innovation Centre, 2 Royal College St., London NWI ONH, England (“Lipoxen”); Baxter Healthcare SA (“BHSA”), a corporation organized and existing under the laws of Switzerland, and Baxter Healthcare Corporation (“BHC”) having its principal place of business at One Baxter Parkway, Deerfield, Illinois 60015 (BHSA and BHC collectively referred to as “Baxter”) to amend the terms of that certain Exclusive Research, Development and License Agreement between the Parties dated August 15, 2005, which was amended pursuant to that certain amendment between the parties dated on or about December 15, 2006 (together the “Agreement”). Lipoxen and Baxter may be referred to herein indi
STOCK PURCHASE AGREEMENTStock Purchase Agreement • February 18th, 2015 • Xenetic Biosciences, Inc. • Pharmaceutical preparations • New York
This STOCK PURCHASE AGREEMENT (this “Agreement”), dated as of January 29, 2014, is by and among Xenetic Biosciences, Inc., a Nevada corporation (the “Company”), and Baxter Healthcare SA (the “Investor”).
AMENDMENT NO. 1 TO STOCK PURCHASE AGREEMENTStock Purchase Agreement • February 18th, 2015 • Xenetic Biosciences, Inc. • Pharmaceutical preparations • New York
This AMENDMENT NO. 1 (this “Amendment”), dated as of February 14, 2014, amends that certain Stock Purchase Agreement, dated as of January 29, 2014 (the “Agreement”), by and between Xenetic Biosciences, Inc., a Nevada corporation (the “Company”), and Baxter Healthcare SA (the “Investor”).
DATED AUGUST, 10 2010 LIPOXEN TECHNOLOGIES, LTD. - and - BAXTER HEALTHCARE CORPORATION AND BAXTER HEALTHCARE SA AMENDMENT NUMBER FOUR TO THE EXCLUSIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTExclusive Research, Development and License Agreement • February 18th, 2015 • Xenetic Biosciences, Inc. • Pharmaceutical preparations
FROM: [ILLEGIBLE] PHONE NO. : 00442076811314 13 DEC. 2006 01: 58 PM P1Research, Development and License Agreement • February 18th, 2015 • Xenetic Biosciences, Inc. • Pharmaceutical preparations
This is an amendment to the Research, Development and License Agreement (“R&L AGREEMENT”) entered into on August 15, 2005, by and between Lipoxen Technologies Limited, a company registered in England and Wales with company number 03401495 and having its registered office at Suite 303, Hamilton House, Mabledon Place, London WC1H 9BB (“LIPOXEN”); Baxter Healthcare SA (“BHSA”), a corporation organized and existing under the laws of Switzerland, and Baxter Healthcare Corporation (“BHC”) having its principal place of business at One Baxter Parkway, Deerfield, Illinois 60015 (BNSA and BHC collectively referred to as “BAXTER”).
AGREEMENT ON CO-DEVELOPMENT AND THE TERMS OF EXCLUSIVE LICENCE between - and-Agreement on Co-Development and the Terms of Exclusive Licence • February 18th, 2015 • Xenetic Biosciences, Inc. • Pharmaceutical preparations
EXCLUSIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTExclusive Research, Development and License Agreement • February 18th, 2015 • Xenetic Biosciences, Inc. • Pharmaceutical preparations • Illinois
This Agreement (“AGREEMENT”) is made and entered into August 15, 2005 (the “EFFECTIVE DATE”) by and between Lipoxen Technologies Limited, a company registered in England and Wales with company number 03401495 and having its registered office at Suite 303, Hamilton House, Mabledon Place, London WC1H 9BB (“LIPOXEN”); Baxter Healthcare SA (“BHSA”), a corporation organized and existing under the laws of Switzerland, and Baxter Healthcare Corporation (“BHC”) having its principal place of business at One Baxter Parkway, Deerfield, Illinois 60015 (BHSA and BHC collectively referred to as “BAXTER”). LIPOXEN and BAXTER may be referred to herein individually as a “PARTY” and collectively as the “PARTIES.”
DATED SEPTEMBER, 15 2010 LIPOXEN TECHNOLOGIES, LTD. - and - BAXTER HEALTHCARE CORPORATION AND BAXTER HEALTHCARE SA AMENDMENT NUMBER FIVE TO THE EXCLUSIVE RESEARCH, DEVELOPMENT AND LICENSE AGREEMENTExclusive Research, Development and License Agreement • February 18th, 2015 • Xenetic Biosciences, Inc. • Pharmaceutical preparations
